AUTHORS
Joselle M Cook, M.D., Mark Wieland, MD2, Michael Howe3, Hong Wei Tang, PhD4, Mahek Bai, MS5, Wilson Gonsalves, MD6, Battalo Bona7, Xaiden White8, Michelle Ivy, MA9, Mohamed Ibrahim10, Rahma Warsame, MD11, Celine Vachon, PhD12, Shaji Kumar, MD13, S. Vincent Rajkumar, MD14, Linda Baughn, PhD15
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 ASH Research Collaborative Patient Collaboration Team, Washington DC, District of Columbia, United States
10 Wellshare International, Mankato, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
Monoclonal gammopathy of undetermined significance (MGUS), the obligate precursor to multiple myeloma (MM), occurs two- to three-fold more frequently in individuals of African than European ancestry. However, most genomic studies aggregate African ancestry despite extensive genetic diversity across the continent, and no study has examined MGUS prevalence in East African populations. We hypothesized that East African genomic ancestry would be associated with intermediate MGUS prevalence compared with African American populations (which are enriched for West Arican ancestry) and European populations. Exploratory analyses evaluated ancestry-specific frequencies and effect sizes of established MGUS/MM susceptibility loci.
Methods:
The MGUS Awareness and Genetics Insights Campaign (MAGIC-1) is the first prospective, community-based MGUS screening study in East African populations. East African adults residing in Minnesota, recruited through primary care clinics and a community-engaged outreach partnership, underwent serum mass spectrometry screening for monoclonal gammopathies and germline genotyping. Germline data were merged with the 1000 Genomes Phase 3 reference panel. Principal Components Analysis (PCA) and supervised ADMIXTURE (K=22) characterized ancestry; thirty-three previously reported MM susceptibility loci were evaluated with MGUS using additive logistic regression with Firth correction.
Results:
350 participants were enrolled, with mass spectrometry results available for the first 298 individuals. The cohort consisted primarily Somali (43.6%), Ethiopian (18%), Kenyan (11.3%) participants. MGUS prevalence was 11.1% (33/298; 95% CI, 7.7-15.2%), similar to published prevalence data using sensitive mass spectrometry in European ancestry populations (10.8%),1 but lower than published African American cohorts (16.5-17%)2. Median age at MGUS diagnosis was 61 years (range, 40-77), with a median M-protein concentration of 0.027 g/dL. PCA demonstrated a distinct East African ancestry profile that was incompletely represented in existing genomic reference panels. Exploratory germline analyses (12 MGUS-positive, 79 MGUS-negative) identified positive associations of MGUS with loci at PREX1 (rs6090899; OR 3.11, P=0.037) and CCDC71L (rs11762574; OR 2.94, P=0.045).
Conclusions:
MAGIC-1 demonstrates a genetically distinct East African cohort that is incompletely represented in current reference panels. Despite shared continental African ancestry, MGUS prevalence more closely resembled that reported in European ancestry populations than the African American (West African enriched) cohorts. With distinct ancestry structure and strong associations at established susceptibility loci, these findings suggest that aggregating genetically diverse African populations may obscure biologically meaningful differences in inherited MGUS susceptibility.
Vachon et al Blood Adv. 2022 Jun 28;6(12):3746-3750.
El Koury et al . Lancet Haematol. 2022 May;9(5):e340-e349.
DISCLOSURES
Joselle M Cook, M.D.: Kite Pharmaceuticals - Honoraria; Janssen Pharmaceuticals - Research Funding; Regeneron - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)